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Abstract The rate of iron release from HepG2 liver cells was 
increased not only by extracellular apotransferrin, but also by 
diferric transferrin, in a non-additive, concentration-dependent 
manner and to a similar magnitude. This suggests that rapid 
equilibration between receptor-mediated uptake and the release 
process determines net iron retention by the liver. Release was 
also accelerated by ceruloplasmin; most importantly, the effect 
of this protein was greatest when iron release was occurring 
rapidly, stimulated by apotransferrin, or under conditions of 
limited oxygen. Thus iron release involves both apotransferrin 
and ferrotransferrin, with ceruloplasmin playing a role in tissues 
with limited oxygen supply, as in the liver in vivo. 
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1. Introduction 
Ceruloplasmin, the copper-containing serum protein, has 
been postulated as the critical ferroxidase for over 30 years. 
Whilst there is no doubt that oxidation is necessary, and that 
ceruloplasmin is biochemically capable of this role, there has 
been little evidence to date that this occurs in a cellular or in 
vivo environment. 
Recent reports of hepatic accumulation of iron stores in 
patients with a hereditary ceruloplasmin deficiency [1] have 
confirmed that this copper-containing ferroxidase plays a 
role in mobilizing iron from tissues stores. A number of early 
animal studies also demonstrated that this was likely to be the 
case, for instance Osaki et al. [2] showed that it could accel-
erate iron release from the perfused liver, while the iron-bind-
ing protein apotransferrin alone appeared to have little effect. 
However, these experiments did not address the question of 
whether the ceruloplasmin-catalyzed release required apo-
transferrin as an acceptor. Free iron is inherently toxic, being 
a potent catalyst for the synthesis of free oxygen species; in 
vivo, therefore, iron is usually complexed to either transferrin 
or ferritin. In previous work investigating the mechanisms of 
iron homeostasis in isolated rat hepatocytes, we found that 
release from hepatocytes of newly acquired iron could occur 
simultaneously with the uptake process and that this release 
could be accelerated by the addition of apotransferrin [3], and 
yet we found no evidence for the presence of receptors specific 
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for apotransferrin on these cells. In support of this role for 
transferrin in iron release, Baker et al. showed that the release 
of iron from freshly isolated rat hepatocytes, labelled in vivo 
with o9Fe, was accelerated by chelators, serum and apotrans-
ferrin [4], although the transferrin effect was not observed by 
all workers [5]. 
The oxidation state of the iron is a crucial factor in its 
mobilization. Iron is bound to transferrin in the ferric, iron 
(III) state, yet most intracellular iron is released from ferritin, 
the primary intracellular iron storage protein, in the ferrous 
iron (II) form. An oxidation step is therefore required before 
this iron may be effectively mobilized outside the cell. 
We were therefore lead to re-examine the release of iron 
from liver cells, and to determine how both transferrin and 
ceruloplasmin influence the release. Here, we show that both 
iron- and apo- transferrin accelerate iron release from the 
human hepatoma cell line HepG2, and that this release rate 
is greatly enhanced by ceruloplasmin. Interestingly, this en-
hancement is greatest under conditions of low oxygen tension, 
and therefore where the rate of spontaneous iron oxidation is 
lowest. 
2. Materials and methods 
2.1. Materials 
Media, sera and tissue culture plastics were obtained from Life 
Technologies (Paisley, Scotland, UK) while bovine serum albumin 
(BSA, fraction V), was from Sigma Chemical Co. (Poole, Dorset, 
UK). The bovine albumin was shown to be free of transferrin by 
radial immunodiffusion against anti-bovine transferrin antisera (rab-
bit) and by the absence of iron-binding capacity using the ferrozine 
method [6]. Chelex 100 was bought from BioRad Laboratories (Brom-
ley, Kent, UK) and human ceruloplasmin from Green Cross Corp. 
(Osaka, Japan). This source of ceruloplasmin was the highest quality 
available; the protein was verified by us to migrate as a single band on 
electrophoresis and to have an Am)IAmi of 0.047, comparable to 
highly purified protein previously described [7]. Unless otherwise 
stated other chemicals were of analytical grade from Fisher Scientific 
(Loughborough, UK). 
2.2. Cells 
The human hepatoma cell line, HepG2 [8], was grown in minimum 
essential medium (MEM) containing 10% fetal bovine serum (FBS), 
penicillin, streptomycin and glutamate. Cells were removed from 
dishes using trypsin/EDTA, washed 3 times in MEM with 10% 
FBS, counted and 3 X106 cells were added to 6-well polystyrene plates 
(10 cm2) 24 h before use. After experimental incubations cell viability 
was checked using trypan blue exclusion and lactate dehydrogenase 
release (Sigma LDH colorimetric assay) and was never less than 95%. 
2.3. Transferrin labelling 
Human apotransferrin (Boehringer-Mannheim, Lewes, UK) was 
loaded to 100%> saturation with 69FeCl3 (Amersham International 
pic, Amersham Bucks) using a 20-fold excess of citrate to complex 
the iron as described by Cavill [9] and an ion exchange resin to 
remove uncomplexed iron citrate. Specific activity of the 59Fe-trans-
ferrin was 1.1-1.2 cpm/pg Fe (1500 cpm/g transferrin protein). The 
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methods used to label human diferric transferrin with 125I (Amersham 
International, Bucks, UK) have been described in full elsewhere [10]. 
2.4. Transferrin binding, iron uptake and cell loading 
Analysis of 125I-labelled transferrin binding to adherent cells was 
done as described before [11]. To characterize iron uptake B9Fe-trans-
ferrin (40 ug/ml) was added to triplicate wells (3X106 cells/well) in 
MEM/1% BSA (1 ml) under 5% C02/air and uptake followed for up 
to 6 h. Uptake was stopped by the addition of ice-cold phosphate-
buffered saline, the wells were washed 3 times and cells dissolved in 
NaOH for counting in the y-counter. To pre-load HepG2 with radio-
iron, 59Fe-transferrin was added to cells in 6-well plates to give a final 
concentration of 25 ng/ml diferric transferrin. Incubation was contin-
ued for 18 h at 37°C in an atmosphere of 5% C02/air, after which the 
cells were cooled to 4°C and washed 3 times in cold medium contain-
ing 1% BSA. Using this procedure the total 69Fe loaded into the 
samples of 3X106 cells in the experiments shown was in the range 
9402-25384 cpm (8.2-22.1 ng Fe). 
2.5. Cell incubation for iron release 
MEM containing 1% BSA (2 ml), which had previously been passed 
through a column of Chelex-100 to remove any iron, as described 
previously [12] was added to dishes containing cells pre-loaded with 
69Fe, following two washes in medium. The cells were incubated for 
two periods of 15 min in fresh medium to remove any residual la-
belled transferrin. Fresh medium (1 ml) was added together with test 
agents, to triplicate wells, and the cells were placed in an 5% CCVair 
atmosphere at 37°C for incubation for up to 24 h. For experiments at 
low oxygen tension, cells were cultured in sealed flasks containing 10% 
air/N2. The experiments were repeated on at least three separate oc-
casions. The 59Fe content of the supernatant was analyzed by count-
ing samples of the supernatant (0.5 ml), in an LKB/Wallac RackGam-
ma counter. Total 59Fe content of a sample of the cells was also 
measured. 
3. Results 
The HepG2 cells used for these experiments, which ex-
pressed 1.4X105 transferrin receptors per cell, were loaded 
with 59Fe using labelled diferric transferrin, uptake from 
which occurred specifically via the receptors, since 96% was 
blocked by a 20-fold excess of unlabelled diferric transferrin 
(data not shown). Subsequent release of this labelled iron was 
linear with time when cells were incubated in medium alone or 
in medium containing apotransferrin. Fig. 1 shows the release 
of iron over a 24 h period, and it is apparent that iron release 
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Fig. 1. Time course of iron release from HepG2 cells. Cells were 
pre-loaded with 59Fe for 18 h, washed and then re-incubated in 
fresh iron-free MEM containing 1% BSA with ( A ) or without (•) 
human apotransferrin (200 u.g/ml). Shown is the mean±SD (« = 3) 
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Fig. 2. Effect of apotransferrin and diferric transferrin on iron re-
lease from HepG2 cells. (A) After pre-loading, cells were incubated 
for 18 h with increasing concentrations of apotransferrin (•) or di-
ferric transferrin (■). (B) As with (A) but cells were incubated with 
increasing diferric transferrin with (•) or without apotransferrin (■) 
at 500 |ig/ml present throughout. 
the addition of apotransferrin accelerates the release by ap-
proximately 40%. 
The effect of apotransferrin was further investigated by 
culturing cells overnight in medium containing increasing con-
centrations of apotransferrin. The effect of apotransferrin was 
concentration-dependent and saturable, with the maximum 
effect being reached with 200 ug/ml apotransferrin (Fig. 2A). 
Unexpectedly, however, when this experiment was performed 
using iron-saturated transferrin, a very similar effect on iron 
release was observed (Fig. 2A). 
Experiments were therefore performed to determine if the 
iron-releasing effects of apo- and diferric transferrin were ad-
ditive. Cells in the presence or absence of an excess of apo-
transferrin were incubated in increasing concentrations of di-
ferric transferrin. Again the effect of diferric transferrin alone 
approached saturation by 200 ug/ml (Fig. 2B); however, there 
was no additional effect of diferric transferrin when excess 
apotransferrin (500 Ug/ml) was present throughout. When 
the experiment was reversed and apotransferrin was titrated 
in the presence of excess diferric transferrin, a very similar 
picture was observed (data not shown), suggesting that there 
is a single pool of iron from which either apo- and diferric 
transferrin can accelerate release. 
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Fig. 3. Effect of apotransferrin and ceruloplasmin on iron release 
from HepG2 cells. Pre-labelled cells were incubated with two con-
centrations of ceruloplasmin and apotransferrin at 0 (■), 100 ( A ) , 
200 ( T ) or 500 ( ♦ ) ug/ml for 18 h and the release of 59Fe moni-
tored. 
The effects of ceruloplasmin in this in vitro system were 
then investigated by adding human ceruloplasmin to the cell 
cultures. Fig. 3 shows that when iron was released into me-
dium containing little (100 u.g/ml) or no apotransferrin, cer-
uloplasmin did not significantly affect the release rate. How-
ever, when the background rate of release was accelerated, by 
the addition of larger amounts of apotransferrin, then there 
was a significant effect elicited by ceruloplasmin. At 500 |J,g/ml 
transferrin, 32 (tg/ml of ceruloplasmin increased iron release 
by 40% in the experiment shown. These results therefore in-
dicate that ceruloplasmin was particularly active in conditions 
where the iron release from the cells was occurring rapidly. 
It has been shown previously that release of iron from hep-
atic cells can be accelerated in conditions of low oxygen ten-
sion [4]; our preliminary experiments confirmed this also to be 
the case with the HepG2 cells (data not shown). We therefore 
investigated whether ceruloplasmin might also be more signif-
icant under conditions of limited oxygen. Incubation of cells 
under low oxygen with both apotransferrin (20 u,g/ml) and 
ceruloplasmin showed an augmentation of iron release by 
nearly 40% of that caused by apotransferrin alone (Table 1). 
This is in contrast with the release at normal oxygen concen-
tration, where ceruloplasmin had no discernable effect on re-
lease to medium containing 20 (tg/ml apotransferrin. At low 
apotransferrin concentrations, therefore, the action of cerulo-
plasmin on iron release is significant only when limited oxygen 
is present. 
Table 1 
Effect of oxygen, ceruloplasmin and apotransferrin on iron release 
from HepG2 cells 
Additions % Control release 
None 100 ±15.5 
Apotransferrin (20 ug/ml) 104.5 ± 3.4 
Ceruloplasmin (32 ug/ml) 99.9 ± 5.4 
Both 142.7 ±10.4 
59Fe-loaded cells were incubated under 10% air/90% N2 with the ad-
dition of apotransferrin and/or ceruloplasmin. Cell viability did not 
differ during the 3 h incubation. The level of release with both pro-
teins added was significantly (P<0.05) higher than the other values. 
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4. Discussion 
We found that iron release from the HepG2 cells occurred 
at a constant rate over the course of 24 h (Fig. 1). This linear 
release has also been shown with both short-term [13] and 
long-term cultures of rat hepatocytes [5] and suggests rapid 
equilibration of the radiolabelled iron taken up from trans-
ferrin with the intracellular pools of iron. 
The release of iron could be accelerated by the addition of 
apotransferrin (Figs. 1 and 2), supporting previous findings 
with both the perfused rat liver [14] and with suspensions of 
isolated hepatocytes [15]. However, in neither of these systems 
could release of iron be increased by increasing the apotrans-
ferrin concentration, suggesting that the rate of release is pre-
dominantly modulated by intracellular factors. Here, we 
found that the iron release could be greatly enhanced by add-
ing more apotransferrin (Fig. 2A) and, perhaps more surpris-
ingly, that diferric transferrin could also enhance the release 
(Fig. 2A). Others have shown such an effect of ferric trans-
ferrin on release of iron from Be Wo Chorion carcinoma cells, 
and suggested that the diferric transferrin first had to be con-
verted to apotransferrin [16]. However, if this were the case 
here, or if this effect had been due to contamination of the 
diferric transferrin with apotransferrin (or vice versa), then 
different potencies for the two forms might have been ex-
pected, and this was not observed (Fig. 2A). The effects 
were not additive, since the addition of iron-transferrin to 
incubations containing a saturating amount of apotransferrin 
failed to augment the release (Fig. 2B). A possible explanation 
for these effects is that the two forms of transferrin are access-
ing the same intracellular pool of iron, with the apotransferrin 
accelerating its release by providing a large iron-binding pool 
to accept iron, and the receptor-mediated endocytosis of di-
ferric transferrin 'chasing' it out by obliging the cell to take up 
unlabelled iron. The concentration-dependent effect of apo-
transferrin indicates that it is acting as more than simply a 
passive acceptor of iron in the extracellular medium. In pre-
vious work we found no evidence of receptors specific for 
apotransferrin on hepatocytes [3]; apotransferrin is neverthe-
less able to bind to the standard transferrin receptor [17] and 
so it is possible that this receptor facilitates transferrin binding 
to iron either at the cell surface or within the cell. 
The mechanism of iron release from liver cells has long 
been thought to involve the oxidation of ferrous to ferric 
iron, and much of the basis for this comes from the effect 
of the ferroxidase ceruloplasmin on the release. Very early 
work showed that ceruloplasmin augmented the release of 
iron from the perfused rat liver to apotransferrin [2]. A 
more recent study confirms that a similar mechanism is im-
portant during iron absorption from the gut, and in particular 
for the release at the contraluminal side into the portal blood. 
Here, iron was found to be in the ferrous state and cerulo-
plasmin accelerated its release into the portal blood by cata-
lyzing the oxidation of ferrous iron by means of its high 
Fe(II): oxygen oxido-reductase activity [18]. We have now 
shown that this ceruloplasmin-mediated acceleration of iron 
release occurs directly on HepG2 liver cells. The action of 
ceruloplasmin was noted only in the presence of high concen-
tration transferrin (> = 200 (J,g/ml; Fig. 3). It is possible that 
at low transferrin concentrations, the rate of spontaneous ox-
idation is sufficient to manage the corresponding slow iron 
release rate; at higher release rates, however, an exogenous 
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ferroxidase activity, such as that provided by ceruloplasmin, is 
required. 
The action of ceruloplasmin on apotransferrin-mediated 
iron release is influenced not only by the apotransferrin con-
centration (as shown above), but also by the ambient oxygen 
concentration. When the iron release under low ambient oxy-
gen was studied, ceruloplasmin augmented the rate induced by 
apotransferrin (Table 1); unlike the effect in ambient oxygen, 
this increase occurred even at the low apotransferrin concen-
tration of 20 ug/ml. These experiments suggest that the fer-
roxidase activity of ceruloplasmin may only become impor-
tant when iron release is occurring rapidly or when the 
amount of oxygen is limited. It is possible that, when the 
rate of release is low, released iron may be oxidized by 
dissolved molecular oxygen, but when the rate of release is 
higher or the supply of oxygen is limited a ferroxidase in the 
form of ceruloplasmin is required. Culture medium has an 
oxygen concentration of about 216 |iM while blood oxygen 
is about 53-120 uM [19]. Deep within the liver it may well be 
even lower [20] and so ceruloplasmin-catalyzed oxida-
tion of iron for binding to apotransferrin [19] may be critical 
to prevent a rise in free iron under these low oxygen condi-
tions. 
Clinical observations support the involvement of cerulo-
plasmin in iron balance. Recently, two separate clinical stud-
ies have reported genetically confirmed ceruloplasmin muta-
tions resulting in truncated and thus disfunctional proteins. In 
both cases, this was associated with systemic and pathological 
iron deposition, primarily in the liver but also elsewhere 
[21,22]. In a third report, not only were hepatic iron deposi-
tion and low serum iron accompanied by aceruloplasminae-
mia, but intravenous administration of ceruloplasmin consid-
erably increased iron mobilization [1]. 
In man, as other species, ceruloplasmin is a known acute 
phase protein, rising in conditions of infection and inflamma-
tion, which are known to pose a disruptive threat to intra-
cellular and extracellular iron balance [23]. Our results indi-
cate that ceruloplasmin has a function as a major modulator 
of hepatocellular iron release, and thus of systemic iron ho-
meostasis. 
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